NCT00093366View on ClinicalTrials.gov

Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2004

Study Completion Date

July 31, 2006

Conditions
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
Interventions
BIOLOGICAL

etanercept

DRUG

arsenic trioxide

Trial Locations (1)

98109-1024

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00093366 - Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter